In 2006, the incidence was 1 in 110 children, and by 2008, the incidence had increased to 1 in 88 children
Ewing, B., Hillier, L., Wendl, M
(2025) called the absence of clinical permeation data "surprising" given how widely GHK-Cu is marketed
AAV PhyTip columns | Automated purification of AAV serotypes Automated purification of adeno-associated viruses using CaptureSelect AAVX resin for high selectivity, 60-80% recovery, and fast, consistent results
These reductions indicate that intranasal GHK-Cu copper peptide not only mitigates amyloid accumulation but also potentially slows early neurodegenerative processes characteristic of AD pathology
However, this response is often a sign that the bacterial overgrowth is being successfully addressed